|
|
| Considering outsourcing development and manufacturing? The Outsourced Pharma Capacity Update (OPCU), a free, interactive, digital event, convenes the industry's foremost CDMOs to provide up-to-date and direct insights into their available capacity and services, alongside specific facility and equipment updates. Discover the July 2025 event’s presenting sponsors in this newsletter to learn how they are best suited to help you to navigate the path to approval and commercialization. |
|
|
|
Novartis Contract Manufacturing | Novartis Contract Manufacturing introduces their fill and finish solutions and capacity. Explore an overview of the aseptic network of Novartis and the capabilities of each site. | Request Information | Novartis Contract Manufacturing |
|
|
PCI Pharma Services | PCI is positioned to meet the future of sterile pharmaceutical development and manufacturing with technology and solutions for high-value biologics, complex formulations, and lyophilized drug products. | Request Information | PCI Pharma Services |
|
|
Afton Scientific | Gain an overview of a new state-of-the-art Groninger filling line’s capabilities, production scale-up timelines, and how this new infrastructure supports product flexibility and long-term growth for partners. | Request Information | Afton Scientific |
|
|
INCOG BioPharma Services | INCOG's balanced framework addresses the unique challenges of sterile manufacturing by integrating risk-based decision making with systematic capacity planning. | Request Information | INCOG BioPharma Services |
|
|
LARGE MOLECULE DRUG SUBSTANCE & DEVELOPMENT |
|
|
Resilience US, Inc. | Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing. | Request Information | Resilience US, Inc. |
|
|
Novartis Contract Manufacturing | Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. Specifically, understand capabilities in mammalian cell culture manufacturing and microbial fermentation. | Request Information | Novartis Contract Manufacturing |
|
|
Cytovance Biologics | Thomas Kohl, Director of Business Development, shares microbial and mammalian capabilities and available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients. | Request Information | Cytovance Biologics |
|
|
FUJIFILM Biotechnologies | Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes. | Request Information | FUJIFILM Biotechnologies |
|
|
Aragen | Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L with a DP filling line and ADC conjugation suite set to redefine bioproduction in India. | Request Information | Aragen |
|
|
|
ReciBioPharm | ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Choose a CDMO with complete end-to-end services and in-house analytical capabilities. | Request Information | ReciBioPharm |
|
|
Alcami | Alcami’s laboratory services can support many drug substance or drug product modalities, all product phases, and specialty laboratory services, including in-house microbiology, raw materials, and analytical development. | Request Information | Alcami |
|
|
KBI Biopharma | Review real examples of how KBI Biopharma has supported its partners through transparency that empowers, integration that simplifies, methods that de-risk, and experience that accelerates. | Request Information | KBI Biopharma |
|
|
Catalent | Pedro Morales, Director, Scientific Advisor of Biologics Analytical Services, explores how Catalent delivers tailored solutions through deep expertise and advanced capabilities. | Request Information | Catalent |
|
|
|
Lonza | Leveraging Lonza's deep ADC expertise and experience, successfully develop high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing. | Request Information | Lonza |
|
|
Simtra BioPharma Solutions | With more than 65 years of sterile injectable manufacturing experience, Simtra offers world-class GMP sterile fill and finish services, deep scientific and technical expertise, and a uniquely collaborative approach. | Request Information | Simtra BioPharma Solutions |
|
|
MilliporeSigma | With more than 15 years of experience as conjugation and linker-payload CDMO, MilliporeSigma has a proven track record of supporting clinical programs from IND to PPQ for commercialization. | Request Information | MilliporeSigma |
|
|
|
|